thinkstockJuly 28, 2015: Markets opened higher on Tuesday after the Shanghai market closed with a modest loss compared with Monday’s 8.5% dive. U.S. consumer confidence came in lower than expected and home…
ThinkstockPfizer Inc. (NYSE: PFE) reported second quarter 2015 results before markets opened Tuesday morning. The company reported quarterly adjusted diluted earnings per share (EPS) of $0.56 and revenues of $11.9 billion. In…
Paul Ausick Wikimedia CommonsBefore the market opens on Tuesday morning, Pfizer Inc. (NYSE: PFE) is scheduled to report second-quarter results. The company is expected to post earnings per share (EPS) of $0.52 on revenues…
Paul Ausick ThinkstockThe short interest data have been released for the July 15 settlement date. Pharmaceutical companies are usually involved in a lengthy process in getting their drug candidates to market through clinical trials.…
ThinkstockPharmaceutical and Biotech investors are about to get a real show for earnings this week. Big Pharma will bring earnings from Dow Jones Industrial Average companies Merck & Co. Inc. (NYSE: MRK)…
A new report from Jefferies updates the firm's top global pharmaceutical stocks to buy, and these picks make sense for investors now.
The June 30 short interest data have been compared with the previous figures, and across the selected pharmaceutical stocks, short interest decreased.
thinkstockJuly 9, 2015: Markets opened higher on Thursday and that’s when the major indexes posted their daily highs. New claims for unemployment benefits remain at close to the averages for full employment…
A new report from UBS highlights three stocks that the firm likes best now. Not only do they all pay a solid dividend and have a good potential for growth, they all…
thinkstockJuly 7, 2015: Markets opened slightly higher on Tuesday but a reversal took just moments to set in and U.S. equities traded mostly lower for the remainder of the day. Commodities of…
How much are big pharmaceutical companies really spending to get their drugs out there in the public eye?
The June 15 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks, short interest is mixed.
The May 29 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest is down.
Credit Suisse has updated its autoimmune market model and it sees implications for all of the large cap U.S. pharmaceutical companies in its coverage.
This coming week is likely to be a serious one in the fight against cholesterol. FDA panels are evaluating more than just one drug candidate.
